SREBF1 and metabolic dysfunction-associated steatohepatitis: Experiments using humanized mice created by knocking in microRNA (miR)-33b into an intron of Srebf1 show that suppression of miR-33b by nucleic acid drugs is useful for the treatment of NASH.